Medicover

* Q2 broadly in line across most line items * '26e-'28e adj. EBITDA -0.7%/-0.4%/-0.4% on weaker Romania * FVR unchanged at SEK 190-270 on minor estimate revisions Broadly in line, Romania weighs Revenue grew 7.3% y-o-y to EUR 640m, with org. growth acceleratin...

* -1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2 * Cons estimates likely unchanged * Trading at 10.2x '26e EV/EBITDA Q2 results: In line with expectations Medicover reported a second quarter in line with cons. Q2 sales were EUR 640m (0% vs ABGSCe, 0...

* Q2'26 numbers due on 22 July at 07:45 CET * Minor estimate changes, margins unchanged * Fair value range kept at SEK 190-270 Q2'26 expectations For Q2, we expect Medicover to perform broadly in line with Q1'26. In Poland and Romania, government funding...

* Strong Q1 beat with 110bps margin expansion on adj. EBITDA * Adj. EBITDA up 1% for '26e-'28e on Q1 beat * FVR unchanged at SEK 190-270 on minor estimate revisions A solid start to '26 despite weather drag Q1 was 8%/6% above ABGSCe/Infront consensus...

* 8%/6% adj. EBITDA vs ABGSCe/Infront cons in Q1 * Cons estimates likely up 1-3% on adj. EBITDA '26e * Model proved itself despite the weather headwind we flagged Q1 results Medicover reported a strong start to '26 with sales in-line vs cons and a clear...

* Q1'26 numbers due on 29 April at 07:45 CET * Near-term caution, but the model should continue to prove itself * Fair value range down to SEK 190-270 (200-280) Q1'26 should be marked by cold weather We expect colder-than-usual temperatures and severe...